Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 12Terminated 4Recruiting 3Unknown 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Carcinoma, Non-Small-Cell Lung 59Squamous Cell Carcinoma of Head and Neck 38Nasopharyngeal Carcinoma 27Lung Neoplasms 26Biliary Tract Neoplasms 24Uterine Cervical Neoplasms 23Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 19Cholangiocarcinoma 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 14Ovarian Neoplasms 14Neoplasms 14Neoplasm Metastasis 13Esophageal Neoplasms 13Colorectal Neoplasms 12Carcinoma 12Stomach Neoplasms 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Carcinoma, Transitional Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Recurrence 6Pancreatic Neoplasms 6Nasopharyngeal Neoplasms 5Gallbladder Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5

Interventions

Cyclophosphamide 8fludarabine 6cabozantinib 5Temozolomide 4Doxorubicin 4Zoledronic Acid 3X-Rays 3Vincristine 3Methotrexate 3Ifosfamide 3Gemcitabine 3Cisplatin 3irinotecan sucrosofate 2atezolizumab 2Surgical Procedures, Operative 2Sunitinib 2Specimen Handling 2Radiosurgery 2Phantoms, Imaging 2Mesna 2Magnetic Resonance Spectroscopy 2Irinotecan 2Eflornithine 2Disulfiram 2Biopsy 2vactosertib 1trilaciclib 1trametinib 1talazoparib 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Osteosarcoma × Cisplatin × Clear all
NCT05691478 2026-05-27

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡